(MENAFN- Trend News Agency) China is in talks with Pfizer Inc to secure a licence that will
allow domestic drugmakers to manufacture and distribute a generic
version of the U.S. firm's COVID-19 antiviral drug Paxlovid in
China, three sources said, trend reports citing reuters .
China's medical products regulator - the National Medical
Products Administration (NMPA) - has been leading the talks with
Pfizer since late last month, one of the sources with knowledge of
the matter said.
Beijing is keen to finalise licensing deal terms before the
Lunar New Year which begins on Jan. 22, the source said.
MENAFN06012023000187011040ID1105394679
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.